Loading
collectionsCollection
OncoKB
Tells you, for a given mutation, whether an approved or investigational drug exists and how strong the evidence is.
Overview
OncoKB holds curated levels of evidence for the clinical actionability of somatic alterations, so that for a given mutation a reader can see whether an approved or investigational drug exists and how strong the evidence is. Memorial Sloan Kettering maintains it; it is free for academic use with a commercial licence, and was recognised by the FDA as a human variant database in 2021. Levels 1 to 4 grade therapeutic evidence and R1 and R2 mark resistance; an API is available and it is used by cBioPortal and many molecular tumour boards. On OnCo it sits under the technology Comprehensive genomic profiling and the related record Cancer variant knowledgebases and molecular tumour boards, and it is cited by the bottleneck Knowledge reaches practice too slowly and by several ideas.
Holds
Curated levels of evidence for the clinical actionability of somatic alterations.
Licence
Free for academic use; commercial licence
Maintainer
Memorial Sloan Kettering
Dataset registry
Size: Precision oncology knowledge base with FDA-recognised levels of evidence
Access: registered
Consent and reuse: Free academic licence; commercial licence.
All datasets and the models trained on them →Similar pages
- CollectioncBioPortal for Cancer Genomics
Shares Every tumour genomic report machine-readable and deposited nationally, Cancer variant knowledgebases and molecular tumour boards, Pool every immunotherapy trial's biomarker data into one commons, Clinical NGS bioinformatics and variant interpretation.
- IdeaDecision support that cites the exact trial and guideline line it relies on
Shares A tumour board assistant that cites its evidence and tracks outcomes, An open knowledge graph linking trials, results, biomarkers, drugs and recommendations, Knowledge reaches practice too slowly.
- CompanyCaris Life Sciences
Shares Every tumour sequencing report lists open, nearby, matched trials pulled live, Every tumour genomic report machine-readable and deposited nationally, Comprehensive genomic profiling.
- IdeaA randomised trial of AI-generated treatment recommendations versus tumour boards
Shares A tumour board assistant that cites its evidence and tracks outcomes, Knowledge reaches practice too slowly.
- TermTargeted panel sequencing
Shares Actionable genomic biomarkers, Comprehensive genomic profiling.
- IdeaA public API serving the current standard of care for any cancer, stage and biomarker
Shares An open knowledge graph linking trials, results, biomarkers, drugs and recommendations, Knowledge reaches practice too slowly.
- CompanySOPHiA GENETICS
Shares Clinical NGS bioinformatics and variant interpretation, Comprehensive genomic profiling.
- CollectionAACR Project GENIE
Shares Every tumour genomic report machine-readable and deposited nationally, Pool every immunotherapy trial's biomarker data into one commons, Check whether a tumour can still show itself to the immune system.
technologies
institutions
terms
ideas
A tumour board assistant that cites its evidence and tracks outcomesAn open knowledge graph linking trials, results, biomarkers, drugs and recommendationsCheck whether a tumour can still show itself to the immune systemEvery tumour genomic report machine-readable and deposited nationallyEvery tumour sequencing report lists open, nearby, matched trials pulled liveGroup trials by broken mechanism, not by organ or single mutationLabel every biomarker claim with an evidence phase, like drugsPool every immunotherapy trial's biomarker data into one commons
collections
bottlenecks
Open-source projects
All open source in oncology →Open-source projects that are the code behind this collection or publish it, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
Memorial Sloan Kettering's precision oncology knowledge base of the clinical effect of genomic alterations. The server code is open; the curated content is free for academic research after registration and licensed for commercial use.